US
vaccine policy creates ‘huge opportunity’ for Europe
Novel
mRNA technology is one area where Europe could lead.

US
Secretary of Health and Human Services Robert F. Kennedy Jr (R) speaks as US
President Donald Trump attends a campaign rally in Florida, U.S. on Oct. 23,
2026. | Brendan Smialowski/AFP via Getty Images
October
30, 2026 6:17 pm CET
https://www.politico.eu/article/us-vaccine-policy-creates-huge-opportunity-for-europe/
U.S.
research cuts and vaccine skepticism have delivered Europe an opportunity to
establish itself as a leader in science — especially developing in
immunizations.
That’s
particularly true for innovative technologies like mRNA — scientists’
latest vaccine discovery first used in the Covid-19 shots.
Since
taking office in January 2025, the Trump administration has slashed funding for
the National Institutes of Health, repeatedly suggested a link between vaccines and autism,
canceled hundreds of millions of dollars in funding for mRNA vaccine research
and overhauled a committee of vaccine experts.
This
allowed Europe to siphon researchers and vaccines developers and champion its
medicines regulator for it steadfast scientific positions.
“I see a
huge opportunity for the [European Medicines Agency] to become more of a key
reference for countries,” said Heidi Larson, professor of anthropology, risk
and decision science at the London School of Hygiene and Tropical Medicine and
founding director of the Vaccine Confidence Project.
“They’re
an incredibly valuable asset for Europe and, in the current environment, [they]
could play an even more important global role,” she told POLITICO.
The
European Medicines Agency — the European Union’s drugs regulator — has long
positioned itself as a trustworthy beacon of science.
“We can
provide fact-based, neutral information” to vaccine and drug developers, EMA
Executive Director Emer Cooke told journalists Wednesday during an event at its
office in Amsterdam. “We want to be there ... as a source of trusted
information that you can rely on.”
The mRNA
opportunity
Novel
mRNA technology is one area where Europe could lead.
The Trump
administration canceled some $500 million in grants and contracts dedicated to
mRNA research and development last year.
“We
reviewed the science, listened to the experts and acted,” Health Secretary
Robert F. Kennedy Jr. said at the time. The U.S. Biomedical Advanced Research and
Development Authority terminated 22 mRNA vaccine development investments
“because the data show these vaccines fail to protect effectively against upper
respiratory infections like COVID and flu,” he said. Funding would shift toward
“safer, broader vaccine platforms that remain effective even as viruses
mutate,” Kennedy added.
For
researchers and developers, however, this sent a signal.
A researcher works on an mRNA transcription reaction in
Orleans, France on Nov. 18, 2025. | Jean-Francois Monier/AFP via Getty Images
“Some of
the policies being promoted [by the U.S.] are just not reliable,” said Larson,
who is also founding director of the Vaccine Confidence Project. “Public
decisions like not funding mRNA sends a signal that they don’t trust it,” she
added.
“You have
a vacuum created by the U.S. right now,” said Sibilia Quilici, head of industry
lobby Vaccines Europe. “Europe, especially EMA, has already communicated … that
they are welcoming the mRNA innovation happening here in Europe.”
Some
developers are already choosing Europe for their work.
“We are
seeing developers increasingly come to EMA first, particularly in areas such as
mRNA technology, because they trust our scientific approach and our ability to
engage with innovative technologies,” Marco Cavaleri, head of public health
threats at the EMA, told POLITICO. “[The] EMA has become an important reference
point globally for regulatory science.”
The EU
was the first market globally to authorize Moderna’s combination Covid-19 and influenza
shot this year. In the U.S., Moderna faced setbacks after the Food and Drug
Administration asked for more data for its flu shot.
The
market gap
But being
a scientific powerhouse is not enough.
“Obviously,
the U.S. remains a huge market, and Europe needs to keep working to attract
innovation,” Cavaleri said.
Despite
its commitment to supporting biotechnology innovation, Europe is still
grappling with a fragmented market, pricing and reimbursement challenges and unstable manufacturing capacities.
This year
alone, German biotech BioNTech announced it was closing its Covid-19 vaccines
manufacturing sites in Germany, slashing one-fifth of its workforce, or up to
1,800 jobs, and British pharmaceutical company GSK said it was shutting a
vaccine factory in Germany.
“mRNA is
a crucial technology platform for vaccines that we must have the capacity to
produce in Europe at all costs,” said Renew MEP Stine Bosse, who is pushing to
ensure technology platforms such as mRNA are eligible for more incentives under
the Biotech Act.
Europe
has “strong regulatory systems,” said Quilici, with the EMA and national
medicines authorities “doing fantastic work in ensuring rigorous and
evidence-based review of any technologies, any products.”
The new
EU Biotech Act also recognizes the importance of the sector, including vaccine
developers, she said.
But
funding remains Europe’s “weakest point,” Quilici said. “Should Europe decide
to invest seriously in its immunization innovation, manufacturing and access,
it has a unique opportunity to gain a competitive edge.”







